1. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. (January 2021) Authors: Garmezy, Benjamin; Schaefer, Jordan K.; Mercer, Jessica; Talpaz, Moshe Journal: Blood reviews Issue: Volume 45(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. Issue 6 (2nd May 2017) Authors: Kandarpa, Malathi; Wu, Yi‐Mi; Robinson, Dan; Burke, Patrick William; Chinnaiyan, Arul M.; Talpaz, Moshe Journal: American journal of hematology Issue: Volume 92:Issue 6(2017:Jun.) Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38–44]. (June 2019) Authors: Gerds, Aaron T.; Tauchi, Tetsuzo; Ritchie, Ellen; Deininger, Michael; Jamieson, Catriona; Mesa, Ruben; Heaney, Mark; Komatsu, Norio; Minami, Hironobu; Su, Yun; Shaik, Naveed; Zhang, Xiaoxi; DiRienzo, Christine; Zeremski, Mirjana; Chan, Geoffrey; Talpaz, Moshe Journal: Leukemia research Issue: Volume 81(2019) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dasatinib dose management for the treatment of chronic myeloid leukemia. Issue 8 (25th January 2018) Authors: Talpaz, Moshe; Saglio, Giuseppe; Atallah, Ehab; Rousselot, Philippe Journal: Cancer Issue: Volume 124:Issue 8(2018) Page Start: 1660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. Issue 5 (29th May 2021) Authors: Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Jourdan, Eric; Silver, Richard T.; Schouten, Harry C.; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Tang, Derek; Abraham, Pranav; Lord-Bessen, Jennifer; Rose, Shelonitda; Guo, Sh... Journal: HemaSphere Issue: Volume 5:Issue 5(2021) Page Start: e562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Issue 6 (17th April 2020) Authors: Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean‐Jacques; Jourdan, Eric; Silver, Richard T.; Schouten, Harry C.; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Shen, Juan; Berry, Tymara; Brownstein, Carrie; Mesa, Ruben A. Journal: American journal of hematology Issue: Volume 95:Issue 6(2020:Jun.) Page Start: 594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Hematology clinic: chronic myelogenous leukemia. (1st November 2013) Authors: Weber, Alissa A.; Talpaz, Moshe Journal: Hematology Issue: Volume 18:Number 6(2013) Page Start: 372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Hematology clinic: chronic myelogenous leukemia. (November 2013) Authors: Weber, Alissa A.; Talpaz, Moshe Journal: Hematology Issue: Volume 18:Number 6(2013) Page Start: 372 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. (September 2016) Authors: Dorer, David J.; Knickerbocker, Ronald K.; Baccarani, Michele; Cortes, Jorge E.; Hochhaus, Andreas; Talpaz, Moshe; Haluska, Frank G. Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. (September 2016) Authors: Dorer, David J.; Knickerbocker, Ronald K.; Baccarani, Michele; Cortes, Jorge E.; Hochhaus, Andreas; Talpaz, Moshe; Haluska, Frank G. Journal: Leukemia research Issue: Volume 48(2016:Sep.) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗